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While indicated for schizophrenia and acute mania, ziprasidone’s evidence base and use in clinical practice extends
beyond these regulatory approvals. We, an invited panel of experts led by a working group of 3, critically examined
the evidence and our collective experience regarding the effectiveness, tolerability and safety of ziprasidone across
its clinical uses. There was no opportunity for manufacturer input into the content of the review. As anticipated,
ziprasidone was found to be effective for its indicated uses, although its utility in mania and mixed states lacked
comparative data. Beyond these uses, the available data were either unimpressive or were lacking. An attractive
characteristic is its neutral effect on weight thereby providing patients with a non-obesogenic long-term treatment
option. Key challenges in practice include the need for dosing on a full stomach and managing its early onset
adverse effect of restlessness. Addressing these issues are critical to its long-term success
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Antipsychotic medications, including second generation
agents (e.g. clozapine olanzapine, quetiapine, risperi-
done), have been prescribed more frequently, alone and
in combination, and for an increasing breadth of indica-
tions in the last decade internationally [1-3]. These
medications are used to treat schizophrenia and related
psychotic disorders, as well as other conditions includ-
ing mood, anxiety, and behaviour disorders. With the
availability of a variety of antipsychotics each with a
unique mix of advantages and disadvantages, clinicians
and patients navigate treatment choices to identify pre-
ferred options. How do clinicians and patients make
these decisions? Choosing an antipsychotic can depend
on multiple complex factors. Following treatment
selection, the immediate and real challenge of working
towards achieving agreed upon goals of therapy begins
(e.g., reduction in symptoms, relapse prevention, recovery).
The plan for this paper was to update previous work [4]
and also introduce new information from a consensus* Correspondence: david.gardner@dal.ca
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reproduction in any medium, provided the orpanel of Canadian experts who met to develop a set of
informed, clinically relevant suggestions for clinicians on
the appropriate use of ziprasidone [4]. The original paper
focused on schizophrenia and related psychotic disorders.
This paper expands the focus to include bipolar disorder,
major depression, and use in special populations. Adverse
effects are extensively reviewed along with dosing and
switching issues.Methods
A panel of twelve psychiatrists and two pharmacists
with relevant antipsychotic related research and clinical
expertise were convened on April 16, 2010 in order to
discuss and synthesize suggestions for the clinical use of
ziprasidone based on current research and clinical
experiences. Funding was obtained as an unrestricted
grant from Pfizer Canada’s community investment fund-
ing opportunity [5]. DG and SK served as the co-chairs
for the meeting and AM led the development of the
manuscript. At no time did the manufacturer or any of
its representatives have any input into the manuscript.
There were no representatives present during the meet-
ing proceedings and they were not privy to the content
of any version of the manuscript. Psychiatrists involvedl Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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co-chairs though not all were able to participate. New
panel members, also invited by the co-chairs, with
relevant clinical and research expertise were added to
the panel based on pre-identified areas of interest and
referrals from other panel members. Members were
delegated a specific clinical area to critically analyze and
present at the meeting. As well, approximately two
hours were allotted and used to discuss time-intensive
topics that were not sufficiently addressed by individual
presentations. Prior to the start of the presentations,
participants were asked to record in writing and verbally
state to the group any potential conflicts of interest
related to the pharmaceutical industry (e.g., grants,
honoraria, advisory boards, investments, etc.) during
the previous two years. During the development of this
manuscript, all members were provided with two oppor-
tunities for critical and constructive feedback. This
manuscript represents a synthesis of information from
individual presentations, collective discussions, an ex-
tensive examination of the evidence base, and feedback
from all panel members.
The following specific and general topics related to
ziprasidone were sent to participants as requirements to
be presented and discussed at the meeting: pharmacol-
ogy, schizophrenia, early psychosis, bipolar disorder,
major depression, adverse effects, cardiometabolic risk,
children and adolescents, elderly, dosing by indication,
and switching. Instructions were provided that presen-
tations should cover relevant and critically appraised lit-
erature and include presenters’ clinical insights on their
specific topic. Participants were offered assistance with
conducting literature searches for their content area by
the project leaders DG and AM and a research associ-
ate. When assistance with literature searches was
requested, a comprehensive search of PubMed, Embase,
ClinicalTrials.gov, Web of Science, the Cochrane
Library, and a related references search of individual
articles as well as review of references within papers was
performed. Appropriate MeSH and text words were
chosen based on the topic and no limits were applied




Ziprasidone exhibits high binding affinity (inhibitory con-
stants shown as pKi with lower numbers indicating higher
affinity) for select dopamine (D2: 3.1 nM; D3: 7.2 nM),
serotonin (5-HT2A: 0.39 nM; 5-HT2C: 0.72 nM; 5-HT1A:
2.5 nM; 5-HT1B/1D: 2.0 nM; 5-HT7: 9.3 nM), and adrener-
gic (α1: 13.0 nM) receptors and moderate affinity for the
histaminic H1 (47 nM) and dopamine D4 (32 nM) recep-
tors. It distinguishes itself from other antipsychotics withits agonist action at the 5-HT1A receptor and balanced
reuptake inhibition actions at serotonin (53 nM) and
noradrenaline (48 nM) transporters [6-8]. Refer to Table 1
for receptor binding affinities among commonly used
antipsychotics.
Several pharmacologic actions of ziprasidone have
long been predicted to confer an antidepressant and
anti-anxiety effect with chronic use. Serotonin and nor-
epinephrine transporter inhibition is dose dependent
with similar in vitro affinity as tricyclic antidepressants
[7,8,12]. In vivo, the clinical significance of its monoami-
nergic reuptake inhibition may be limited by plasma
protein binding or be clinically relevant only at higher
than currently recommended daily dosages.
Activity at 5-HT1A is similar to that of buspirone
[13]. Its inverse agonist activity at 5-HT2A receptors
disinhibits dopamine neurotransmission in the nigros-
triatal, tuberoinfundibular, and mesocortical pathways
possibly explaining its reduced risk of parkinsonism
and hyperprolactinemia [7,14]. This action also disin-
hibits dopamine release in the mesocortical pathway
linking the brainstem and prefrontal cortex, an action
that is putatively linked to a reduction of the negative
and cognitive symptoms of schizophrenia [15].
Also predicting a low rate of movement problems,
such as parkinsonism, dystonia, and dyskinesia, is its
relatively high 5-HT2A/D2 receptor affinity ratio [16-18].
Antagonism of the 5-HT2C receptors disinhibits both
dopamine and norepinephrine neurons in the cortex. This
activity is predictive of improvements in cognitive and
affective abnormalities as well as excitement and possibly
agitation [13,15,19,20]. 5-HT2C antagonist activity has
also been associated with weight gain in some models,
for example the 5-HT2C knockout mouse model of
obesity [21]. However, the association between 5-HT2C
antagonist activity and weight gain among antipsycho-
tics is weak [22].
Ziprasidone has a low affinity for histaminergic1 (H1),
muscarinic1 (M1), and α1-noradrenergic receptors. Among
the biogenic amine receptors, H1 antagonist activity is
associated with sedation and a valid predictor of weight
gain liability [22]. Low affinity for α1-adrenergic receptors
predicts a lower likelihood of orthostatic hypotension and
sedation and low affinity for M1 receptors predicts low
rates of anticholinergic side effects including dry mouth,
blurry vision, urinary retention, constipation, memory
impairment, confusion, and delirium.
Using an imaging protocol, 60% or greater D2 dopa-
mine receptor occupancy is generally predictive of anti-
psychotic activity. An in vivo PET study examining the
affinity of ziprasidone for dopamine (D2) and serotonin
(5-HT2) receptors observed that optimal D2 receptor
occupancy occurs at the upper end (≥120 mg/day) of
the recommended dosage range [23].
Table 1 Antipsychotic affinities (Ki) and target daily dosing range in schizophrenia [7,9-11]
Antipsychotic Very high High Moderate Low Negligible
daily dose (Ki < 1.0) (Ki 1.0–9.9) (Ki 10–99) (Ki 100–999) (Ki ≥1000)
Ziprasidone 5HT2a (0.4) 5HT1a (2.5) ** α1 (13) D1 (130) M1 (5100)
120-160 mg 5HT2c (0.7) D2 (3.1) D4 (32) α2 (310)
D3 (7.2) H1 (47)
5HT7 (9.3) NAuptake (48)
5HTuptake (53)
5HT6 (76)
Aripiprazole D2 (0.3) ** 5HT1a (1.7) ** D4 (44) M1 (>1000)





Risperidone 5HT2a (0.3) α1 (1.4) 5HT2c (10) 5HT1A (210) 5HTuptake (1400)
4-6 mg D2 (2.2) H1 (19) D1 (580) 5HT6 (2000)
5HT7 (3.0) M1 (2800)
D3 (9.6) NAuptake (28,000)
D4 (8.5)
α2 (5.1)
Paliperidone 5HT2a (1.0) α2 (17) 5HT1A (590) M1 (3570)
6-9 mg 5HT7 (1.3) H1 (32) D1 (670)
α1 (4.0) D4 (30)
D2 (4.8) 5HT2c (71)
D3 (6.9)
Olanzapine H1 (2.8) 5HT2c (10) α2 (170) 5HT1a (2100)
10-20 mg 5HT2a (3.3) 5HT6 (10) 5HT7 (250) NAuptake (2000)





Clozapine H1 (1.8) 5HT6 (11) D4 (54) 5HTuptake (3900)
200-500 mg M1 (1.8) 5HT2c (17) D2 (130)
α1 (4.0) α2 (33) 5HT1a (140) **
5HT2a (8.9) 5HT7 (66) D3 (240)
D1 (290)
NAuptake (390) *
Quetiapine H1 (8.7) α1 (15) M1 (100) α2 (1000)
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Table 1 Antipsychotic affinities (Ki) and target daily dosing range in schizophrenia [7,9-11] (Continued)
400-800 mg D2 (180) D1 (1300)
5HT2a (220) 5HT2c (1400)
5HT1a (230) ** 5HT7 (1800)
D3 (320) D4 (2200)
NAuptake (680)* 5HT6 (4100)
5HTuptake (>18,000)
* Quetiapine’s active metabolite N-desalkyl-quetiapine inhibits NA uptake (35 nM). Clozapine’s active metabolite N-desmethyl-clozapine also has a low affinity for
NA uptake inhibition.
** Partial agonist. Quetiapine’s active metabolite N-desalkyl-quetiapine is a 5HT1a partial agonist (191 nM). Clozapine’s active metabolite N-desmethyl-clozapine is a
5HT1a partial agonist (105 nM).
5-HT: serotonin; D: dopamine; H: histamine; M: muscarinic cholinergic; α: alpha-adrenergic.
Lower values (shown in parentheses) indicate higher affinities at receptors or greater inhibition of pre-synaptic neurotransmitter uptake. Antipsychotics used in
relatively small daily doses are unlikely to have clinical effects at receptors for which they have low affinity, unlike antipsychotics used at high daily doses.
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Ziprasidone achieves peak concentration approximately
6–8 hours post ingestion and steady state concentration
by the end of the second day of dosing. The typical half-
life is 6–10 hours, though individual patient values have
ranged between 3 and 18 hours [14]. It is extensively
metabolized, two-thirds by aldehyde oxidase, of which
there are no known clinically relevant inducers or inhi-
bitors, and one-third by P450 oxidation (3A4 > > 1A2).
Potent inducers and inhibitors of CYP 3A4 may result
in clinically relevant changes in ziprasidone clearance.
Unlike most antipsychotics, bioavailability of ziprasi-
done is approximately halved in the fasting state. To
ensure optimal absorption, a meal of at least 500 kcal is
recommended with each ziprasidone dose [24]. While
absorption appears to be consistent whether the meal is
low or high in protein or fat content, there are no data to
indicate that simple carbohydrate meals (e.g., glucose-
based energy drinks) are sufficient for absorption. It is
important to note that dose and concentration are linearly
correlated when taken with a ≥500 kcal meal but not in
the fasting state. As such, doubling the dose in the fasting
state does not achieve the same systemic bioavailability as
taking the usual dose with food (see Figure 1). Table 2
provides calorie count examples of common foods.Figure 1 Affect of food on ziprasidone absorption. Reproduced with pSchizophrenia
The Canadian guidelines for the treatment of schizophrenia
outline specific stages of therapeutic management [26].
These include individuals in the acute phase of illness
requiring urgent care, first episode with little previous
antipsychotic treatment, stabilization phase, stable phase,
and those with multiple episodes. In addition, within these
populations, subgroups such as those with persistent posi-
tive or negative symptoms, depression, suicidality, violent
behaviours, inadequate response and gender differences
are considered. Ziprasidone has been evaluated for many
of these indications with analyses specific to some of the
subgroups but details were not included in the 2005 iter-
ation of the Canadian guidelines.
Evidence from ziprasidone randomized trials in patients
with schizophrenia has been synthesized in a Cochrane
Review [27]. The analysis included nine trials with the
comparators amisulpride (not available in Canada), cloza-
pine, olanzapine, quetiapine, and risperidone. In general,
the quality and quantity of available data as well as extent
of comparators was limited. Ziprasidone was determined
to be less efficacious than olanzapine and risperidone
based on PANSS total score and PANSS positive symptom
subscore, especially in medium-to-long term studies [27].
Olanzapine was also associated with fewer hospitalizationsermission [25].
Table 2 Calories of common foods [25]
Item Approx. kcal value
1 large bagel 350
1 doughnut 120
1 cup of cornflakes cereal 100
Small fast food French fries 230
Ham and cheese sandwich 350
Hamburger, with bun, plain 270
Hotdog, with bun, plain 240
Egg sandwich in English muffin 300
Danish fruit pastry 335
1 egg, boiled 70
2 snack cakes with crème filling 250
1 slice pizza 350




Reproduced with permission [25].
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clozapine in a head-to-head, randomized, double-blind
study of 18 weeks in treatment refractory patients showed
similar reductions in PANSS scores with ziprasidone and
clozapine [28]. Further head-to-head trials are warranted
to replicate these unexpected findings. Studies published
since the review by Komossa et al., are primarily non-
randomized or non-double blind designs [29,30] and sev-
eral extension studies have also been published [31-33].
An extension study of 156 weeks following a 40 week
randomized trial was designed to examine PANSS, quality
of life scale, global assessment of functioning (GAF), and
remission rates [33]. Treatment arms included ziprasidone
80–160 mg/d administered twice daily, ziprasidone 80–
120 mg/d given once daily, and haloperidol 5 – 20 mg/d.
Two hundred and twenty subjects of 599 were offered
participation in the extension study and of these 186
consented to participate. In the 156 week extension
study, mean PANSS negative subscale change scores per
week based on last-observation-carried-forward (LOCF)
were −4.86 (SD 7.64) for ziprasidone 80–160 mg, -3.17
(SD 6.15) for haloperidol 5–20 mg, and −2.87 (SD 6.48)
for ziprasidone 80–120 mg. The least squares mean
results of ziprasidone 80–160 mg/d compared to halo-
peridol were statistically different but not for haloperi-
dol compared to ziprasidone 80–120 mg/d. GAF scores
for either dosage group of ziprasidone were not differ-
ent from haloperidol. In the post-hoc analyses, the rate
of remission as defined by a score of less than or equal
to 3 for at least 6 months on eight PANSS items was
51% in ziprasidone 80–160 mg/d group and 40% in thehaloperidol group. No differences existed for the lower
dose of ziprasidone compared to haloperidol. In another
post hoc analyses of the same trial, Stahl et al., [34]
explored aspects of negative symptoms and functioning.
Kaplan-Meier Survival curves indicated greater rates of re-
mission of negative symptoms with both dosage groups of
ziprasidone versus haloperidol. At 1 year these rates were
approximately 60% and 50%, and 35% for the higher and
lower dose ziprasidone strategies and 35% with haloperidol.
Another year later ~15% more patients in each group
attained remission from negative symptoms. The findings
suggest an advantage for ziprasidone for negative symptoms
and indicate the extended duration of treatment required
to observe substantial improvement in negative symptoms.
Findings also indicated advantage for ziprasidone on 2 of 4
subscales (role functioning and community participation)
of the Quality of Life Scale (QLS).
Early psychosis
Results in first episode psychosis patients have been
published across several papers based on the European
First Episode Schizophrenia Trial (EUFEST) [29,35-38].
EUFEST was an open-label, randomized comparison of
haloperidol, amisulpride, olanzapine, quetiapine and
ziprasidone with a primary outcome of treatment dis-
continuation. Response rates, defined by Boter et al.,
[35] as symptom reduction of ≥50%, at 12 months were
haloperidol 37%, amisulpride 67%, olanzapine 67%, que-
tiapine 46%, and ziprasidone 56%. Remissions lasting at
least 6 months were observed at the following rates:
haloperidol 17%, amisulpride 40%, olanzapine 41%,
quetiapine 24%, and ziprasidone 28% [35].
Davidson et al., [37] reported moderate cognitive
improvements with antipsychotics from the EUFEST data
with no significant differences among agents [37,39]. Des-
pite the younger patient population and use of a different
first generation antipsychotic comparator, these findings
are not dissimilar from the Clinical Antipsychotic Trials of
Intervention Effectiveness (CATIE) results [39,40].
From available data for schizophrenia and first episode
psychosis, aspects of the safety and effectiveness of second
generation antipsychotics versus each other and their first
generation counterparts are debatable [27,41,42]. It appears
from the literature and panel discussions that ziprasidone’s
place in therapy is best considered for patients at risk for
cardiometabolic effects, those susceptible to sedation, and
as a potential first line agent in those with first episode
psychosis.
Bipolar disorder
Second-generation antipsychotic studies in patients
with bipolar disorder [43-46] typically show more bene-
fits in patients with mania versus depression. Study
results for second generation antipsychotics in bipolar
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olanzapine in combination with fluoxetine providing the
most compelling data [47-51]. The World Federation of
Societies of Biological Psychiatry (WFSBP) guidelines
for bipolar depression indicate that the evidence for
ziprasidone is negative [46]. The recent summary of the
negative findings of two randomized, 6 week trials of
ziprasidone monotherapy for people with bipolar
depression sheds light on this issue. Lombardo et al.
presented the results of both the fixed dose (40–80 or
120–160 mg/day), placebo-controlled study and the
flexible-dose (40–160 mg/day), placebo controlled study
[52-54]. Placebo response rates were 49% & 51% per study
and ranged between 46% and 53% with ziprasidone.
Both studies were negative. Similarly, a ziprasidone
augmentation study in bipolar I depression failed to find
a benefit over lithium, divalproex, and lamotrigine
monotherapies [55].
Ziprasidone was superior to placebo in a randomized
trial of patients presenting with depressed mixed states
(i.e., major depressive episode with 2 or 3 manic criteria
symptoms). In an exploratory analysis ziprasidone was
found to be more effective in the bipolar sample com-
pared to the MDD sample (p = 0.036) [56]. Given the
planned inclusion of depressive mixed state in DSM V,
this study may prove to be of interest conceptually.
For patients with mania, some antipsychotics have
been studied more extensively than others. For example,
olanzapine has been supported as effective for not only
the treatment of mania but also as maintenance therapy
for the prevention of manic relapses [57,58] and may
also demonstrate cost-effectiveness [57]. A systematic
review and meta-analysis of randomized controlled
trials of second-generation antipsychotics in the treat-
ment of acute mania (including publications to 2006) is
available [59]. Yildiz et al. [60] also conducted a meta-
analysis of many agents, including ziprasidone, with
purported antimanic effects. The Canadian Network
for Mood and Anxiety Treatments (CANMAT) lists
ziprasidone as one of twelve first-line treatment options
for acute mania and as an option as an adjunctive
therapy in maintenance of bipolar disorder [61]. The
World Federation of Societies of Biological Psychiatry
guideline for treatment of acute mania [45] support
the use of this agent based on their definition of “A”
level evidence, which primarily comes from three trials
[62-64] with further information for recommendations
presented based on cardiovascular safety considerations
and restrictions on use. Pooled estimates [59] derived
from Keck et al. (2003), [62] and Potkin et al. (2005),
[63] that serve as the basis for the majority of supportive
recommendations, demonstrate a standardized mean
difference in YMRS scores of −0.44 (95% CI −0.65 to
−0.23). This effect size estimate indicates that 67% ofthe ziprasidone group did better in terms of mania
symptom reduction than the average placebo patient
improvement [64] This was similar to individual pooled
estimates for other individual second-generation anti-
psychotics (aripiprazole, olanzapine, quetiapine, and ris-
peridone) as well as the combined pooled change (−0.45
(95% CI −0.57 to −0.32)) for the group of antipsychotic
medications [55]. Yildiz et al., [60] meta analyzed data
from Keck et al. (2003), [62] Potkin et al. (2005), [63], and
Vieta et al. (2010), [65] and found a number needed to
treat of 5.9 (95% CI 3.9 - 14.3) for mania management
with ziprasidone compared to placebo. Few data for
head-to-head comparisons are available with the excep-
tion of Vieta et al., [65] who found greater symptom
reduction with haloperidol versus ziprasidone based on
Mania Rating Scale (MRS) scores. Response rates at
week 3 were: haloperidol 55%, ziprasidone 37%, and
placebo 20%. Vieta et al. refer to the lack of equivalence
between the agents’ doses (ziprasidone 116 mg/day vs.
haloperidol 16 mg/day) [65] and others also comment
in general on the relative lack of sufficiently long term
trials of both placebo and head to head trials for inform-
ing decisions [60].
Pooled analyses of the trials by Keck and Potkin for
subgroups of patients with a mixed manic episode and
dysphoric mania are reported as positive trials [66,67].
However, in the dysphoric mania post-hoc analysis for
example, baseline symptoms of depression were subsyn-
dromal (HAM-D baseline ziprasidone 9.6 ± 4.6 and pla-
cebo 8.7 ± 4.1). The clinical relevance of the statistical
difference in mean reduction in HAM-D scores is argu-
ably negligible (ziprasidone −4.2, placebo −2.0). One study
by Weisler et al. (2003), [68] is also cited in guidelines and
other papers as supporting evidence but could only be
found as an abstract.
Bowden et al. (2010), [69] conducted a 6 month,
randomized double-blind trial of ziprasidone or placebo
added to either lithium or valproate in patients with
continued symptoms of bipolar I disorder (mania or
mixed episode). Participants first received ziprasidone
and lithium or valproate for an 8 week open label
stabilization phase. Of the 584 participants that received
ziprasidone add on therapy, 240 were then randomized
to ziprasidone or placebo plus mood stabilizer. Approxi-
mately 67% and 80% of participants were relapse free in
the placebo and ziprasidone groups at 6 months (p = 0.01).
The relapse free data was primarily attributed to differ-
ences in manic episodes for ziprasidone as depressive
episodes were similar between groups. Kaplan-Meier
estimates indicated a significant difference (log rank test
p = 0.0104) for time-to-intervention for a mood dis-
order favouring ziprasidone. The mean difference for
ziprasidone versus placebo in the mania rating scale
(MRS) total score was −3.27 (95% CI −4.91 to −1.62).
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metabolic-related side effects maintain interest in this
medication for bipolar disorder. However, experiences
of agitation and insomnia have limited its clinical utility
in some manic and hypomanic patients. Concomitant
benzodiazepine use in mania trials may have helped to
limit these adverse outcomes.
Depression
The evidence for the use of ziprasidone for the treat-
ment of major depressive disorder (MDD) is sparse. The
argument for evaluating its role for the treatment of
MDD is made from several perspectives including
plausible pharmacological hypotheses and inadequacy
of currently available treatment options.
Other second-generation antipsychotics (e.g., olanza-
pine, risperidone, and quetiapine) have already made
the transition from use for schizophrenia to use in
mania and most recently to depression. Ziprasidone’s
pharmacological actions, including its 5-HT2A antagon-
ism and reuptake inhibition of 5-HT and NE suggest an
antidepressant effect. However, making explicit linkages
between receptor binding profiles and clinical results in
various patient groups is not straightforward. For
instance, a sub-analysis of depression related outcomes
in a meta-analyses of patients with schizophrenia
demonstrated symptom benefits in those antipsychotics
with (e.g., quetiapine) and without (e.g., olanzapine)
5-HT1A partial agonistic effects [70].
It should be noted that, at present, there are no rando-
mized, double-blind, controlled trials of ziprasidone in
MDD published in peer reviewed journals. However, three
monotherapy randomized trials have been completed
(primary data collection ended June 2010 or earlier) and
one ziprasidone augmentation of SSRI treatment study is
expected to be completed in 2013 [71-74]. Methodological
and recruitment details of each can be found at clinical-
trials.gov but no results are provided.
Other second generation agents have more informa-
tion related to depression as acute therapy augmen-
tation strategies. The CANMAT guidelines for the
treatment of major depressive disorder include quetia-
pine as a second-line recommendation [71-74]. In those
patients who have incomplete or non-response to an ini-
tial antidepressant, “first-line” approaches include add-
on therapy with aripiprazole (Level 1), olanzapine (Level 1),
and risperidone (Level 2). Ziprasidone is suggested as
add-on therapy in the third line approach with level 3
evidence [75].
A meta analysis by Nelson and Papakostas (2009)
synthesized information on the use of second generation
agents as augmentation therapy in major depressive disor-
ders [76]. The odds ratio for response, as defined by ≥ 50%
reduction in MADRS or HAM-D score, with secondgeneration antipsychotics was 1.69 (95% CI 1.46, 1.95).
Odds for remission was doubled (OR = 2.00, 95% CI 1.69,
2.37). Second generation agents included in the review
were aripiprazole, olanzapine, quetiapine, and risperidone.
Methodological issues and the unresolved therapeutic
questions of what is the appropriate dose and duration of
second generation antipsychotics remain despite this
meta-analysis. Some agents such as quetiapine have been
studied further since the time of the search conducted by
Nelson and Papakostas, with promising results [77].
Komossa et al. (2010), [78] also published a systematic
review of second generation antipsychotics for major
depressive disorder and dysthymia and noted the relative
lack of available published data for several agents includ-
ing ziprasidone. Two available studies [79,80] were
excluded from their analyses as they were not RCTs [78].
Two open-label randomized ziprasidone studies in
treatment-resistant depression have been published.
Dunner et al. (2007), [81] allocated 54 patients to
combination continued sertraline therapy or add-on
ziprasidone 80 (Z80&S) or 160 mg/day (Z160&S). Mean
change (SE) MADRS scores were −8.3 (2.2) for Z160&S,
-6.0 (1.9) for Z80&S, and −4.4 (2.0) for sertraline alone.
Possibly reflecting the small sample size, differences
among groups were not significant. Differences in re-
sponse (≥50% reduction in MADRS score) and remission
(MADRS score < 10) rates of 6/19 (32%), 4/21 (19%), and
2/20 (10%), and 4/19 (21%), 1/21 (5%), and 1/20 (5%),
respectively, were also not significant. Papakostas et al.
(2004), [80] studied ziprasidone add-on therapy to SSRIs
in a 6 week study with 20 patients, of which 13 completed
the study. In the intention-to-treat analysis 10 of 20
participants achieved a 50% reduction in HAM-D-17
scores and were thus defined as responders. Other small
and uncontrolled investigations [79,82] do not contribute
significant information for therapeutic decision-making.
The available pharmacological hypotheses and sparse
data may warrant further exploration of ziprasidone in
managing patients with MDD.Adverse events
The prevalence and severity of various adverse effects is
heterogeneous amongst antipsychotics but potential con-
sequences can be universal and include impairment in
quality of life, poor adherence, stigmatization, morbidity
and mortality [83]. Similar to other antipsychotics, the
risk:benefit profile of ziprasidone requires careful consid-
eration and panel participants discussed potential merits
of this agent (e.g., metabolic adverse events) alongside
drawbacks (e.g., agitation). Other detailed reviews on these
topics have been published [84]. During the discussions
regarding adverse events, the panel focused on several
clinically concerning or potentially limiting adverse events
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tics to provide context.
Agitation
The group discussed the potential for discontinuation
and other deleterious effects on patient outcomes due
to therapy-related agitation. From the group’s clinical
experience and review of the literature, it was noted that
manifestations of agitation are not well described and
could be classified as illness symptoms (e.g., hypomania)
or referred to as a different adverse effect (e.g., akathisia).
Differences in terminology are also plausible with some
references to activation [85], which may have considerable
symptom overlap with manic or hypomanic symptoms,
akathisia, and agitation. Patients with agitation can dem-
onstrate a variety of behaviours (e.g., pressured or loud
speech, pacing, tapping fingers or feet, starting, moaning,
appearing distracted by an internal stimulus) and also
manifest physiologic changes related to autonomic tone
(e.g., blood pressure) and the musculoskeletal system (e.g.,
muscle tension) [86]. The group discussed the importance
of ruling out and reversing potential contributory etiolo-
gies to the symptoms. As an example, patients with
concurrent substance use problems may describe activa-
tion or appear agitated in relation to the substance
dependence.
There is controversy as to whether the symptoms of
agitation or activation are dose-dependent and whether
any variability exists in terms of commencement of
symptoms in relation to duration of therapy. Clinical
experience within the group supported that agitation at
lower doses is a phenomenon reported clinically by
patients and suggestions were made regarding dose
initiation and up-titration, as discussed later, to enhance
the likelihood of adherence in early stages of treatment.
Exemplifying the challenge of ziprasidone-related agi-
tation, Kaushik (2009) [85] reported activation with
higher, not lower, doses of ziprasidone, and reviews the
related literature and putative mechanisms [15]. Clini-
cians should also be aware of reports of mania like
symptoms associated with the use of ziprasidone when
considering symptoms of activation and agitation [87].
QTc prolongation
QTc prolongation is a risk factor for serious ventricular
dysrrhythmias (e.g., Torsades de pointes (TdP)) and
sudden cardiac death. The frequency of TdP with non-
cardiac classes of medications is not well defined but is
thought to be well below 0.1% [88]. Harrigan et al.
reported on the changes in QTc with 6 antipsychotics in-
cluding ziprasidone [89]. The mean change in QTc (msec)
was 15.9 with ziprasidone, which was approximately 9 to
14 msec more than other included agents (haloperidol,
quetiapine, risperidone and olanzapine) but less thanthioridazine (30.1 msec). Addition of ketoconazole, which
served as a metabolic inhibitor in the study, did not appre-
ciably increase the QTc any further with ziprasidone
(16.6 msec) [89]. The authors also state that at no point
did any participant experience a QTc greater than
500 msec, which is generally considered as approaching
the threshold for TdP [89]. Miceli et al. (2010), [90] exam-
ined the effects of very high dose ziprasidone (up to
320 mg/day) and haloperidol on QTc. The mean QTc
change was 19.5 msec (95% CI 15.5 to 23.4) for ziprasi-
done 160 mg/day and 22.5 msec (95% CI 15.7 to 29.4) at
320 mg/day. One patient of 29 experienced a change in
QTc of 61 msec at the 320 mg/day dose. No patients in ei-
ther treatment arm had a QTc of greater than 450 msec
[90]. Eker et al. (2009) [91] reported on three cases of
potential ziprasidone induced QTc prolongation with one
patient experiencing a QTc of 510 msec with a dose of
240 mg/day. Resolution of QTc prolongation was achieved
in all cases with dose reduction or cessation of ziprasi-
done. Clinical symptoms of prolonged QTc were not
reported. Rocha et al. (2006), [92] reported one older
nursing home patient with a QTc of 505 ms from a base-
line of 450 ms. The per protocol group (n = 15) showed a
29 ms increase in mean QTc (baseline: 409.5 ± 15.5, day
49: 438.5 ± 10.6 ms).
In their meta analyses examining ziprasidone for
schizophrenia, Komossa et al. [27] reported no apparent
differences for prolonged QTc and changes in QTc from
baseline with ziprasidone as compared to clozapine,
amisulpride, olanzapine and risperidone. These findings
are similar to those of Chung and Chua [93].
As of January 31, 2010 in Canada, Health Canada
received nine voluntary, spontaneous reports of QT
prolongation with ziprasidone [94]. This information is
provided with the caveat that spontaneous reports have
important limitations and are not appropriate for deter-
mining probability of adverse events.
Alipour et al. (2010) [95] reported a case of TdP in a
ziprasidone overdose (6 g) with co-ingestants. They
indicate that their case represents the second published
overdose of ziprasidone resulting in TdP (the other case
involved a hypokalemic 30 year old woman) and note
that other overdose reports did not lead to adverse car-
diac outcomes [95,96]. Tan et al. (2009) [97] conducted
a systematic review in order to examine the literature
for cardiovascular effects following second generation
antipsychotic overdoses. In their review, 1 pediatric case
of increased QTc in a child under 7 years of age receiv-
ing a ziprasidone dose of 400 mg was identified. From
case level data in adults 16 years and older, increased
QTc was reported in 13 cases, ventricular arrhythmia
in one, and death in two. Two cases of QTc prolon-
gation occurred while patients were taking both zipra-
sidone and quetiapine in one and ziprasidone and
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stance overdoses with one patient having prolonged
QTc and ventricular dysrrhythmia with suspected co-
ingestion of amantadine, ibuprofen and ziprasidone.
Hypokalemia and bradycardia were features of the
patient’s presentation.
Considerable discussion occurred with the panel regard-
ing routine screening with electrocardiogram (ECG) and
whether it is an effective way to detect individuals at
risk for persistent prolonged QTc interval. ECG is
recommended before initiating treatment with ziprasi-
done in patients with stable cardiac disease or if cardiac
symptoms (e.g., syncope, palpitations, vertigo) occur
during treatment. Clinicians should be knowledgeable
of the contraindications listed in the product mono-
graph and should also consider the many other condi-
tions, population characteristics (e.g., older women),
and medications that can affect parameters of the
cardiovascular system including impulse generation,
conduction, and hemodynamics. The group speculated
that given the best available evidence, duration of use
(since 2001 in the US and 2008 in Canada), and the po-
tential breadth of use for off-label indications in patient
types not usually reflected in clinical trials, if ziprasi-
done was truly associated with a risk of sudden death
from cardiac causes its prevalence would be apparent
from literature and clinical experience. However, con-
cerns exist concomitantly regarding capturing post-
marketing adverse reactions and the voluntary nature
and low levels of reporting by health care professionals
in the Canadian context. Concerns also exist for the
relative low quantity of effectiveness and safety data in
certain populations (e.g. pediatrics) and if off-label use
was to occur in these groups, uncertainty exists as to
the effects on QTc.
Extrapyramidal side effects
In the meta-analysis by Komossa et al. (2009), [27]
various domains of extrapyramidal symptoms (EPS)
were analyzed for ziprasidone versus other comparators
(i.e. amisulpride, quetiapine, olanzapine and risperidone).
There were no statistically significant differences in the
rate of movement related side effects with ziprasidone
versus amisulpride, quetiapine, and olanzapine. The differ-
ence in abnormal movements, akathisia severity, and
parkinsonism was statistically significant in favour of
ziprasidone compared to risperidone, a finding that comes
from a single comparative study [98]. Based on two stud-
ies in the meta-analysis, the rates of antiparkinsonism
medication use were 14.1% with ziprasidone versus 16.6%
with risperidone, with a Mantel-Haenszel estimated risk
ratio of 0.70 (95% CI 0.51, 0.97). The risk of using anti-
parkinsonism medication was significantly increased with
ziprasidone (16.8%) compared to olanzapine (10.9%) witha Mantel-Haenszel risk ratio of 1.43 (95% CI 1.03, 1.99).
Compared to quetiapine, rates were 7.6% with ziprasidone
compared to 3.3% with quetiapine with a Mantel-
Haenszel risk ratio of 2.32 (95% CI 1.07, 5.00). Similar
findings are published by Rummel-Kluge (2010) [99].
From the available literature, arriving at conclusions
with respect to EPS risk remains difficult due to differ-
ences in study design, the perspective of the analyses,
the patient population, and how adverse events were
captured and reported. An analysis by the CATIE inves-
tigators found no significant differences in ratings for
parkinsonism, dystonia, akathisia, or tardive dyskinesia
when examining second-generation agents [100]. When
considering EPS in the context of switching, as per the
results of three 6-week open-label studies, potential
improvements with Simpson-Angus scale scores after
switching from conventional agents and risperidone to
ziprasidone occurred but not when switching from
olanzapine [101].
Regarding serious movement disorders (e.g., oculogyric
crisis, acute and tardive dystonias, tardive dyskinesia,
neuroleptic malignant syndrome), the panel discussed
that from clinical experience the risk of severe EPS
appears to be uncommon or rare with ziprasidone but
can occur. The comparative risk of individual severe
movement disorders is difficult to evaluate because of
their indistinct reporting in clinical trials and overall
infrequency [102-108].
Rash
Pre-marketing trial data represented in product mono-
graph information from the US for ziprasidone indicates
that about 5% of patients receiving ziprasidone devel-
oped rash and/or urticaria.112 Resolution of symptoms
was reported with symptomatic management (e.g. steroids,
antihistamines) and/or discontinuation of treatment [109].
As reported by the manufacturer, treatment emergent
adverse reactions in short term trials of patients with
schizophrenia demonstrated rash in 4% of ziprasidone
patients and 3% of placebo recipients. In bipolar patients,
treatment emergent pruritis was reported in 3.3% of
ziprasidone patients and 2.2% of placebo recipients [14].
Post-marketing information from spontaneous reports
as cited by the manufacturer includes the potential for
angioedema and Stevens Johnson Syndrome although
no causality with ziprasidone has been established [14].
Published cases describe potential ziprasidone-induced
angioedema, urticaria and angioedema, and photoallergic
skin reaction [110-112].
As with any cutaneous reaction, the suspected etiology
and contributing factors requires in depth exploration and
depending on the nature and severity, consultation with
specialists (e.g., dermatologists, immunologists). For zipra-
sidone, it is suggested that the medication be discontinued
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sent and symptomatic treatment to optimize resolution
should be pursued. Expedient consultation with specialists
for advice and recommendations regarding ambiguous
clinical situations of cutaneous reactions may be sought
when pharmacotherapeutic alternatives to ziprasidone are
limited due to individual patient characteristics and/or the
risks associated with discontinuation of treatment are
considered to be dire.
Cardiometabolic risks
Given the concern for potential disparities in the quality
of health care services for patients with mental health
disorders and the higher odds of adverse health related
outcomes including mortality and morbidity, consideration
of therapeutic alternatives that minimize risks is essential.
Differences among antipsychotics are frequently reported
in studies for outcomes that are considered clinical and/or
surrogate in nature (e.g., weight gain, cholesterol, glucose,
etc.) and therefore these risks must be weighted with the
individual patient profile and benefits.
Weight gain
The ideal measure or best discriminator (e.g., BMI,
abdominal waist circumference, etc.) for predicting the
risk of cardiovascular outcomes with respect to adiposity
remains controversial [113,114]. The explicit mechanism
of antipsychotic induced weight gain is not known but
various theories and multifactorial explanations have been
and continue to be explored including significant interest
in genetics [115-122]. Foley and Morley report lower pre-
treatment BMI, younger age, triglyceride levels, more
negative symptoms, antidepressants, and more concomi-
tant medications were predictive of weight gain following
antipsychotics initiation in first episode psychosis patients
[113]. Their findings are consistent with other reviews
[123]. Some researchers and clinicians have also specu-
lated that symptom improvement for some patients may
be correlated with weight gain although currently available
research does not support clinically important improve-
ments in PANSS and CGI with weight gain for patients
with schizophrenia [124].
Weight gain liability varies among the commonly used
antipsychotics. For example, compared to amisulpride,
olanzapine, quetiapine, and risperidone, respectively,
the RR of a weight gain of ≥7% of baseline body weight
with ziprasidone was 0.48 (95% CI 0.18, 1.29), 0.22 (95% CI
0.14, 0.33), 0.45 (95% CI 0.28, 0.74), and 0.49 (95% CI 0.33,
0.74), respectively, identifying a distinct clinical advantage
of ziprasidone therapy [27]. Mean weight change (kg)
favoured ziprasidone compared to olanzapine −3.82
(95% CI −4.69, -2.96), quetiapine −1.20 (95% CI −2.45,
0.05), and risperidone −1.10 (95% CI −2.35, 0.15)
[27]. The systematic review by Rummel-Kluge (2010)similarly found a weight management advantage with
ziprasidone compared to olanzapine −3.82 kg (95% CI
−4.69 to −2.96), quetiapine −1.2 (95% CI −2.45 to 0.05),
and risperidone −1.1 kg (95% CI −2.35 to 0.15) [125]. In
a database analyses, Parsons et al. (2009) [126] exam-
ined data of short and long term placebo and active
controlled trials of various antipsychotics. The long-
term trials for the antipsychotics studied (i.e., haloperi-
dol, olanzapine, risperidone, ziprasidone, and placebo)
included 1649 patients with 450 patients treated for up
to 6 months and 470 patients with potential exposure
for up to one year. For ziprasidone long-term trial data
(N = 1080), the random effects model for a weight gain
of greater than 7% was 12% (95% CI 8%, 16%) and for
weight loss greater than 7% was 16% (95% CI 11%, 21%).
Mean weight change per month was a mean of 0.37
pounds (95% CI −0.83, -0.09) and the median loss was
0.17 pounds [126]. In the CATIE trial (2005) [127],
weight gain of ≥7% from baseline to last observation oc-
curred in 30% of olanzapine, 16% of quetiapine, 14% of
risperidone, 12% of perphenazine, and 7% of ziprasidone
patients.
Weiden et al. (2008) [128] analyzed data from partici-
pants (N = 185) in three ziprasidone pre-marketing (be-
tween 1997 and 1999) extension studies that were
originally 6 weeks in duration and could be extended to
a maximum of 58 weeks. In the first phase of the study
patients were switched from risperidone (N = 43), olan-
zapine (N = 71) and conventional antipsychotics (N = 71)
to ziprasidone. In the extension phase, 61% of parti-
cipants discontinued treatment by 58 weeks with 54%
of those agreeing to participate in the extension study
completing 32 weeks of treatment. Last observation
carried forward and observed case was used for the ana-
lyses. Patients switched from olanzapine and risperidone
lost 4.5 kg and 5.1 kg, respectively (p < 0.01 for both).
There was no statistical difference in weight loss in those
switched from conventional antipsychotics.
Switching to ziprasidone was discussed in the context
of seeking improvement in weight and other metabolic
parameters, however the panel noted that these potential
benefits must be weighed in light of effectiveness and
the chance of successful treatment with sequential
agents [101,129-131].
Cholesterol and glucose
From meta-analytic data of head-to-head comparisons of
second generation agents in schizophrenia [125], ziprasi-
done had a favourable profile as compared to olanzapine
(−15.83, 95% CI −25.72 to −5.95), quetiapine (−16.01, 95%
CI −23.46 to −8.57) and risperidone (−8.58, 95% CI −16.04
to −1.11) for mean difference in cholesterol (mg/dL).
Ziprasidone was significantly different in terms of mean
difference in glucose (mg/dL) as compared to olanzapine
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different from quetiapine and risperidone. Weiden et al.
(2008) [128] also demonstrated improvements in total
cholesterol and triglycerides with the use of ziprasidone as
compared to olanzapine and risperidone.
The link between changes in lipids and glycemic con-
trol and adverse macrovascular and microvascular com-
plications varies among pharmacotherapies, with some
drugs known to cause beneficial effects on surrogate
measures but poor cardiovascular outcomes. As such,
the implications of the variances in negative effects of
antipsychotics on surrogate markers of cardiovascular
disease should not be assumed. Weinmann et al. (2009)
[132] conducted a systematic review examining the
available literature on antipsychotic-related mortality,
including cardiovascular morbidity and mortality, and
found inconsistent findings. The authors also comment
that the long term effects of second generation antipsy-
chotics will require longer term follow-up.
Significant attention and research has also been
devoted to finding interventions to attenuate or mitigate
antipsychotic induced weight gain and related para-
meters (e.g., HbA1c, lipids) [115,126,133-138]. For
example, a recent review by Maayan et al. examined 32
studies with 15 different pharmacological agents as
potential treatments for antipsychotic associated weight
gain [133]. The review revealed an absence of head-
to-head trials for pharmacological options and mixed
results with regard to achieving and sustaining weight
reduction benefits possibly accounted for, in part, by
differences in timing of initiation of therapy. As a result,
the panel discussed a need for additionally focusing
efforts on prevention and health promotion. Continued
study regarding morbidity and mortality trends and the
etiology of these outcomes for those with symptoms of
mental illnesses and disorders is required. Implementa-
tion of evidence-informed standards of care and recom-
mendations for screening, prevention and monitoring
for physical, including cardiometabolic risks, [139] and
mental health care are required.
Ziprasidone use in young and older populations
Children and young adults
The use of second generation antipsychotics in the
pediatric population is controversial and, as accurately
observed by Vitiello et al. [140], practice has expanded
more rapidly than the evidence base. The primary con-
cerns in this population are overuse, off-label use, and
lack of effectiveness and safety data for specific patient
groups and indications [140-160]. Concerns regarding
the long-term safety of these agents require specific
investigation to support informed decisions. For ex-
ample, the cardiometabolic parameters (e.g., weight
gain, cholesterol) potentially influenced by severalsecond generation antipsychotics and the impact of
these changes on health outcomes may not be realized
for a considerable time following exposure [161].
Notably, the second generation antipsychotics are not
approved by Health Canada for use in pediatrics, and in
the US ziprasidone is not indicated as a first-line ther-
apy in pediatric populations. Despite the absence of
regulatory approvals of antipsychotics in pediatrics
internationally (with few exceptions), these medications
are used commonly in pediatrics. A recent study of US
Medicaid recipients in Michigan identified 292 indivi-
duals under 21 years of age receiving ziprasidone
prescriptions in the year following availability on the
market in the US. The majority (58%) of recipients were
between 12 to 17 years. The data also demonstrated that
in 33% of children, ziprasidone was their first anti-
psychotic prescription and of the beneficiaries receiving
ziprasidone 53% had a diagnosis of psychosis [162].
Thirty six percent of prescriptions were written by
general practitioners. These findings suggest a general
willingness to prescribe an untested psychotropic in a
vulnerable patient population.
The use of ziprasidone in the child and adolescent
population was reviewed recently by Elbe and Carandang
(2008) [163]. An updated search did not produce add-
itional relevant information on effectiveness. In clinical
practice ziprasidone would be considered a second-line
treatment for Tourette’s or other tic disorders, bipolar
disorder, and for autism spectrum disorders, [164,165]
and it may be considered in patients in which weight
gain or metabolic adverse effects to other standard
antipsychotics are a particular concern [161,166].
The use of this medication should be weighed in con-
text of the available evidence for efficacy and safety in
pediatrics. To date, two published prospective, double-
blind RCTs, with a combined total of 266 children, are
available that examined ziprasidone for Tourette’s
syndrome [167] and bipolar mania, schizophrenia, or
schizoaffective disorder [168]. The remaining evidence
of effectiveness and safety consists of open-label, non-
randomized trials, with a total of 428 participants. From
the 2008 review by Elbe and Carandang, [163] other
published evidence in the form of retrospective data or
case series contributes information from approximately
225 patients.
From a safety and tolerability perspective, it appears
that sedation and somnolence are the most common
adverse events reported with ziprasidone in pediatric
populations [169]. Reports of serious adverse effects
involving ziprasidone have included neuroleptic malig-
nant syndrome [106,170], EPS [171,172], and changes
in cardiac rate or rhythm including QTc prolongation
[173,174]. Although published case reports are avail-
able, [175,176] accurate estimates of adverse effect
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recommendations for monitoring for some side effects
such as QTc given the finite amount of data available
from studies and post-marketing surveillance. Until
more safety data is available we recommend an ECG at
baseline and at the target dose when used in children
and youth.
Older adults
Despite the warnings of increased risk of death [109]
with the use of second-generation antipsychotics in
older adults with dementia, there continues to be sub-
stantial off-label use in this population. There are no
randomized controlled trials evaluating the efficacy or
safety of ziprasidone in elderly patients [177]. A
Cochrane Review examining atypical antipsychotics for
aggression and psychosis in patients with dementia does
not include ziprasidone [178]. One open-label, flexible
dosing prospective case series of 25 nursing home
patients with dementia, of which 15 completed the
study according to protocol, by Rocha et al. (2006) [92]
showed a significant reduction in the mean total neuro-
psychiatric inventory (NPI) score from baseline 47.1 ±
17.1 (mean ± SD) to 25.8 ± 17.9 at 49 days. From clinical
experiences, appropriate management of agitation, ag-
gression, and confusion, remains complex with few safe
and effective therapeutic alternatives.
Long-term treatment acceptability
Persistence with prescribed treatment is a critical goal
of therapy with antipsychotics 182,183 and yet it remains
overestimated in the clinical setting despite ample
characterization of non-adherence in the literature
[179-183]. Kamossa et al. (2009), [27] reviewed ziprasi-
done versus other atypical agents for schizophrenia and
found premature discontinuation for any reason in 59%
of people randomized to antipsychotic treatment, a
finding matched by others [184]. In the review by
Komossa, the relative risk of leaving studies for any
reason was more likely with ziprasidone as compared to
olanzapine, 1.26 (95% CI 1.18, 1.35), and risperidone,
1.11 (95% CI 1.02, 1.20) [27]. The CATIE investigators
demonstrated all cause discontinuation rates of 64%,
74%, 75%, 79%, and 82% for olanzapine, risperidone,
perphenazine, ziprasidone, and quetiapine, respectively
[127]. A recent naturalistic study in patients with symp-
toms of acute psychosis demonstrated discontinuation
rates of approximately 60% for the second generation
antipsychotics (quetiapine, olanzapine, risperidone and
ziprasidone) within 100 days [181]. Kahn et al., exam-
ined the effectiveness of antipsychotic drugs in first-
episode schizophrenia and schizophreniform disorder and
had 12 month discontinuation rates (any cause) of 72%
(haloperidol), 53% (quetiapine), 45% (ziprasidone), 40%(amisulpride), and 33% (olanzapine) [29]. A study by Olfson
et al. (2011) [160] showed discontinuation rates in the first
180 days with early onset schizophrenia to be above 70%
for all agents including aripiprazole, olanzapine, quetia-
pine, risperidone, and ziprasidone. Many other trials with
ziprasidone in patients with schizophrenia or related
disorders that were small or large in scale and duration
have shown similarly significant discontinuation rates re-
gardless of their design (i.e., prospective or retrospective)
[30,31,33,185,186].
Rates of discontinuation are similarly high for other
mental disorders. Randomized studies in patients with
bipolar disorder demonstrate completion rates of 54%
and 61% for ziprasidone versus 85% and 44% for
placebo [58,59]. Vieta et al. showed completion rates of
45% for haloperidol, 41% for ziprasidone and 28% for
placebo in patients with acute mania in a 12 week study
[60]. In patients with treatment resistant depression
who were randomized to either open-label sertraline
monotherapy or sertraline and ziprasidone (80 or
160 mg), 75%, 50% and 47% of participants completed
the study, respectively [81]. A meta-analysis of second
generation agents, not including ziprasidone, for aug-
mentation therapy in major depressive disorder demon-
strated an odds ratio of 1.30 (95% CI 1.09, 1.57) for
discontinuation for any reason [75].
Dosing and switching challenges and solutions
Dosing
Evidence informed clinical experience suggests that
optimal dosing of ziprasidone in first episode patients
appears to be in the range of 80–160 mg/d, for chronic
schizophrenia 120–160 mg/d, for bipolar mania 120–
160 mg/d. While evidence of benefit in major depres-
sion is lacking, when tried, a lower dose of 20–80 mg/d
is recommended.
Dosing should be started at 40 mg twice daily with
meals for inpatients and 20 to 40 mg twice daily for out-
patients. For example, a suggested schedule for an early
psychosis outpatient is: Day 1: 20 mg AM, 40 mg PM;
Day 2: 40 mg AM, 60 mg PM, Day 3: 60 mg AM,
60 mg PM, then reassess. The second dose of the day
should be taken with the last meal of the day, and
patients should be informed about the importance of
consuming 500 kcal of food with each dose of their
ziprasidone.
The traditional approach to dosing antipsychotic
medications is to start at a low dose and gradually titrate
upward based on patient tolerance and response. This
approach has been challenged of late with findings that
a more rapid titration, for example with quetiapine, may
increase the chance for successful long-term therapy
[187,188]. This may also apply to ziprasidone [185,189].
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Figure 2 All-cause discontinuation survival curves by ziprasidone dose. Reproduced with permission [185].
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placebo-controlled, fixed-dose studies (n = 842) of
ziprasidone. The rate of all cause discontinuation was
lowest with ziprasidone at its highest dose, primarily
driven by its greater efficacy. The respective rates of
discontinuations for all reasons, lack of efficacy, and
adverse effects by dose were: placebo: 50%, 31%, 2%;
40 mg/d: 41%, 24%, 2%; 80 mg/d: 46%, 22%, 2%;
120 mg/d: 38%, 18%, 7%; and 160 mg/d: 27%, 11%, 4%.
Figure 2 illustrates greater treatment persistence isTable 3 Ziprasidone dosing recommendations* [9,109,163]
Start dose & titration rate
Schizophrenia (adults) 20-40 mg twice daily
↑ every 1–3 days
Bipolar mania (adults) 40 mg twice daily
↑ every 1–2 days
Elderly No differences in the pharmacoki
elderly patients. A limited numbe
trials who demonstrated similar to
be necessary unless other conside
indicated for elderly patients with
Children There is limited experience with z
support its safety and efficacy at a
with tics was ~30 mg/day. In a la
the mean dose was 120 mg/day
Special populations Dosage adjustments are generally
reduction of 40-50% is recommen
adolescents, first episode psychos
ethnicity.
Potent inhibitors and inducers of CYP3A4 Dose modification of ziprasidone
for an estimated 30-40% change
CYP3A4 inhibitors (e.g., clarithrom
carbamazepine, St John’s wort).
* All doses to be taken with a meal of at least 500 kcal to ensure adequate and condetectable as early as 7 to 14 days when the higher tar-
get dose of 160 mg/d is prescribed.
Ziprasidone dosing recommendations vary depending
on the diagnosis and age of the patient and should also
be sensitive to patient-specific safety, tolerability and
efficacy issues inferred from past treatment response
and medical considerations [9,109]. For dose guidance
refer to Table 3.
A notable challenge to initiating ziprasidone therapy
is its association with activation and insomnia early inTarget dose range Maximum dose
60-80 mg twice daily 100 mg twice daily
60-80 mg twice daily 80 mg twice daily
netics of ziprasidone were observed in a small study involving healthy
r of elderly with schizophrenia were exposed to ziprasidone in clinical
lerability as adults. These findings suggest that reduced dosing may not
rations are present. Ziprasidone, like other atypical antipsychotics, is not
dementia due the elevated risk of death.
iprasidone in children under clinical trial conditions, as such data to
ny dose is insufficient. Mean dose is one small RCT in children (11.5 y)
rger RCT of older children & adolescents (13.6 y) with bipolar disorder,
in those weighing >45 kg.
not required on the basis of gender, race, or renal function. Dose
ded in the presence of severe hepatic insufficiency and of 20-30% in
is, organic brain syndrome, bipolar maintenance, underweight, and Asian
may be warranted. Pharmacokinetic studies demonstrate the potential
in systemic exposure to ziprasidone when co-administered with potent
ycin, protease inhibitors, ketoconazole) and inducers (e.g.,
sistent absorption.
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have been associated with poorer outcomes. As such,
this panel recommends a more rapid titration schedule
to target doses and, when necessary, the limited-term
use of anxiolytics to support treatment initiation (e.g.,
lorazepam 1–2 mg/day as needed × 7 days). Patients
should be advised that they might experience some rest-
lessness or agitation, which frequently subsides with
dosage escalation and time or may benefit from a short
course of a benzodiazepine. If the presentation is more
fitting with a diagnosis of antipsychotic-induced akathisia,
rapid dosage escalation is not recommended. Rather, anti-
akathisic treatment such as propranolol can be considered
and dosage escalation continued if akathisia subsides.Switching
The method of switching between antipsychotics varies,
however the most commonly applied method is the over-
lapping switch. In doing so, there are multiple factors to
consider before embarking on a switch in antipsychotic
therapy that involves ziprasidone [190-192]. These include
the reason for the switch (e.g., lack of response, into-
lerance, non-adherence), the pharmacologies of the anti-
psychotics being stopped and started (e.g., high or low
antagonist potency at dopamine, histamine, and muscar-
inic receptors), and dosing history (e.g., duration, daily
dose).
Clinical experience suggests that higher doses of a
replacement antipsychotic are usually needed when
previous antipsychotics have proven inadequately ef-
fective and that lower doses are indicated with a history
of intolerance to previous agents. These experience-based
principles apply to dosing targets when switching to
ziprasidone. Also, when the pharmacologies of the out-
going and incoming antipsychotic are at odds with each
other (e.g., high vs. low potency at dopamine, histamine,
or muscarinic receptors) a more careful switch is war-
ranted. For example, when switching from olanzapine,
quetiapine, or clozapine to ziprasidone, an excessively
rapid transition may be associated with activation and
signs and symptoms of cholinergic rebound due to the
rapid loss of the antihistaminc and/or anticholinergic
effects. Attention to sleep hygiene measures (e.g., avoid
late-day use of caffeine and other stimulants, rise at the
same time each day, etc.) and short-term use of sedatives
can help address this when it is necessary to reduce the
doses of these drugs quickly. D2 related adverse effects,
such as EPS, may also worsen transiently due to excessive
D2 blockade if down titration of the current antipsy-
chotic is too slow. This latter issue is especially of con-
cern when switching between risperidone, paliperidone,
or other potent D2 antagonists with longer half-lives
and ziprasidone.Conclusion
The available literature and discussions of clinical ex-
perience reviewed in this paper support the use of
ziprasidone in schizophrenia and bipolar mania. There
is less information available to support its use in other
indications including depression and anxiety or for
special groups including children, youth, and elderly.
Ziprasidone’s main advantages over other antipsycho-
tics include its attractive metabolic effects profile.
Clinicians should prioritize ziprasidone for patients
with pre-existing metabolic issues (e.g., obesity, dyslip-
idemia, impaired glucose tolerance), patients with
metabolic adverse effects to other antipsychotics, and
for patients wishing to mitigate the risk for metabolic
adverse effects when considering their antipsychotic
options. Patients should be informed that ziprasidone
has a high rate of early treatment discontinuation,
primarily due to a lack of efficacy and/or adverse
effects, and that the risk for this is lower with some but
not all other antipsychotics. A remarkable feature is
that ziprasidone clearly needs to be taken with food, an
issue that may underlie a proportion of treatment
failures in trials and clinical practice. As with other
antipsychotics, optimal dosing of ziprasidone has
evolved with experience and new clinical information.
To maximize ziprasidone’s benefits and limit early
intolerance, we advocate targeting the high end of the
dosing range of ziprasidone along with the limited
term use of a benzodiazepine to manage the not
uncommon experience of activation or agitation with
treatment initiation.
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